Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.

Mestre-Durán C, Martín-Cortázar C, García-Solís B, Pernas A, Pertíñez L, Galán V, Sisinni L, Clares-Villa L, Navarro-Zapata A, Al-Akioui K, Escudero A, Ferreras C, Pérez-Martínez A

Open source

DOI: 10.3389/fimmu.2022.1045316
Published: 2022
Container: Frontiers in immunology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fimmu.2022.1045316,
  title = {Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.},
  author = {Mestre-Durán C and Martín-Cortázar C and García-Solís B and Pernas A and Pertíñez L and Galán V and Sisinni L and Clares-Villa L and Navarro-Zapata A and Al-Akioui K and Escudero A and Ferreras C and Pérez-Martínez A},
  year = {2022},
  journal = {Frontiers in immunology},
  doi = {10.3389/fimmu.2022.1045316},
  url = {https://doi.org/10.3389/fimmu.2022.1045316}
}

RIS

TY  - JOUR
TI  - Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.
AU  - Mestre-Durán C
AU  - Martín-Cortázar C
AU  - García-Solís B
AU  - Pernas A
AU  - Pertíñez L
AU  - Galán V
AU  - Sisinni L
AU  - Clares-Villa L
AU  - Navarro-Zapata A
AU  - Al-Akioui K
AU  - Escudero A
AU  - Ferreras C
AU  - Pérez-Martínez A
PY  - 2022
JO  - Frontiers in immunology
DO  - 10.3389/fimmu.2022.1045316
UR  - https://doi.org/10.3389/fimmu.2022.1045316
ER  -

APA

C, M., C, M., B, G., A, P., L, P., V, G., L, S., L, C., A, N., K, A., A, E., C, F., & A, P. (2022). Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2022.1045316

Source records

pubmed · retrieved 2026-09-25T12:52:33.197Z